O retinoblastoma é um tumor maligno ocular com mais frequência na infância e pode causar cegueira e morte.

possui uma incidência de um a cada 15 ou 30.000 nascidos

 

– O retinoblastoma possui uma incidência de um a cada 15 ou 30.000 nascidos vivos, aproximadamente 3% em crianças menores de dois anos de idade e 5% em crianças maiores de cinco anos de idade.

 

– Cerca de 25% apresentam tumor bilateral (hereditário); outros 15% em processo unilateral e hereditário; e 60% com doença unilateral e não hereditária.

 

 

■ Recent advancements in the management of retinoblastoma and uveal melanoma

Amy C Schefler, Ryan S Kim

Fac Rev. 2021; 10: 51.

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8204763/

 

■ Changes in treatment patterns and globe salvage rate of advanced retinoblastoma in Korea: efficacy of intra-arterial chemotherapy

Dong Hyun Lee, Jung Woo Han, Seung Min Hahn et al

J Clin Med. 2021 Nov; 10(22): 5421

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8619482/

 

■ At what age could screening for familial retinoblastoma be discontined? A systematic review

Milo van Hoefen Wijsard, Saskia H. Serné, René H. Otten et al

Cancers (Basel) 2021 Apr; 13(8): 1942

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8072927/

 

■ Current indications of secondary enucleation in retinoblastoma management: a pósiton paper on Behalf of the European Retinoblastoma Group

Christina Stathopoulos, Livia Lumbroso-Le Rouic, Annette C. Moll et al

Cancers (Basel) 2021 Jul; 13(14): 3392

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8303810/

 

■ Introduction of a variant classification system for analysis of genotype-phenotype relationship in heritable retinoblastoma

Isabel Hülsenbeck, Mirjam Frank, Eva Biewald,et al

Cancers (Basel) 2021 Apr; 13(7): 1605

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8037437/

 

 

■ Whole-genome sequencing of retinoblastoma reveals the diversity of rearrangements disrupting RB1 and uncovers a treatment-related mutational signatures

Helen R. Davies, Kevin D. Broad, Zerrin Onadim et al

Cancers (Basel) 2021 Feb; 13(4): 754

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7918943/

 

■ Qumioterapia intrarterial para el manejo del retinoblastoma

J C Gómez-Veja, M I Ocampo-Navia, J José Botero-Trujillo et al

Univ Med 2021, vol 62 (4)

http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S2011-08392021000400007&lng=en&nrm=iso&tlng=es

 

■ Retrato de familiares acompanhantes de crianças e adolescentes atendidos por retinoblastoma no Brasil: Estudo transversal

M I P Messias, G S Bochi, A N F da Silva et al

Research, Society & Development 2021, vol 10 (5)

https://rsdjournal.org/index.php/rsd/article/view/15096/13503

 

■ Long-term of subsequente cancer incidence among hereditary and nonhereditary retinoblastoma survivors

Sara J. Schonfeld, Ruth A. Kleinerman, David H. Abramson et al

Br J Cancer. 2021 Mar 30; 124(7): 1312–1319

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8007574/

 

■ Benign tumors in long-term survivors of retinoblastoma

Milo van Hoefen Wijsard, Sara J. Schonfeld, Flora E. van Leeuwen et al

Cancers (Basel) 2021 Apr; 13(8): 1773

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8068196/

 

■ Subsequent malignant neoplasms in retinoblastoma survivors

Armida W. M. Fabius, Milo van Hoefen Wijsard, Flora E. van Leeuwen, Annette C. Moll

Cancers (Basel) 2021 Mar; 13(6): 1200

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8001190/

 

■ Parenteral occupation and risk of chilhood retinoblastoma in Denmark

Negar Omidakhsh, Johnni Hansen, Beate Ritz, et al

J Occup Environ Med. 2021 Mar 1; 63(3): 256–261

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8259454/

 

■ The impact of cell-free DNA analysis on the management of retinoblastoma

Amy Gerrish, Helen Jenkinson, Trevor Cole

Cancers (Basel) 2021 Apr; 13(7): 157

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8037190/

 

■ Multi-functionalized nanomaterials and nanoparticles for diagnosis and treatment of retinoblastoma

Rabia Arshad, Mahmood Barani, Abbas Rahdar,et al

Biosensors (Basel) 2021 Apr; 11(4): 9

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8066896/

 

■ A hign-risk retinoblastoma subtype with stmnes features, dedifferentiated cone states and neuronal/ganglion cell gene expression.

Jing Liu, Daniela Ottaviani, Meriem Sefta et al

Nat Commun. 2021; 12: 5578

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8458383/

 

■ Response criteria for intraocular retinoblastoma: RB-RECIST

Jesse L. Berry, Francis L. Munier, Brenda L. Gallie et al

Pediatr Blood Cancer. 2021 May; 68(5): e28964

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8049511/

 

■ Retinoblastoma from human stem cell-derived retinal organoids

Jackie L. Norrie, Anjana Nityanandam, Karen Lai,  et al

Nat Commun. 2021; 12: 4535

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8316454/

 

■ A single arm study of systemic and sub-Tenon chemotherapy for groups C and D intraocular retinoblastoma, a Children´s Oncology Group Study (ARET 0231)

Rima F. Jubran, Judith G. Villablanca, Mark Krailo et al

Pediatr Blood Cancer. 2020 Sep; 67(9): e28502

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7857974/

 

■ Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Consultório: Rua Padre Rolim 815/sala 601 – Belo Horizonte/MG/Brasil

Tel: 33245518

CRMMG: 7026

Email: pfleite1873@gmail.com

Blog Internet Médica – www.internetmedica.com.br

Data: janeiro 2022